Skip to main content
SpringerLink
Log in

Gaucher Disease

Pediatric Concerns

  • Therapy In Practice
  • Published:
Pediatric Drugs Aims and scope Submit manuscript

Abstract

Gaucher disease, the most prevalent lysosomal storage disorder, is inherited as an autosomal recessive condition. The gold standard for diagnosis is decreased acid β-glucosidase activity in the lymphocytes or fibroblasts; molecular analysis of mutations allows for some prognostication of disease severity. Prenatal diagnosis and carrier testing for at-risk families are currently available.

There is tremendous phenotypic heterogeneity in the non-neuronopathic form (type I), ranging from clinically asymptomatic to massive hepatomegaly, hypersplenism, growth retardation in children and extensive involvement of bone and lungs. Presence on one allele of the most common mutation, N370S, which is the most prevalent among Ashkenazi Jews for whom there is a predilection for Gaucher disease, is protective of neurological involvement. Some mutations, such as 84GG and IVS2+1, are associated with more severe disease manifestations when appearing as compound heterozygotes with N370S, but when occurring in the homozygous state are not compatible with life. Other mutations, such as L444P, are associated with severe non-neurological disease when occurring as compound heterozygotes with N370S, but when occurring in the homozygous state may be predictive of neurological disease of either acute (type II) or subacute (type III) forms.

In the past decade, enzyme replacement therapy has become available which has resulted in a reduction in liver and spleen volume and consequently improved anemia and thrombocytopenia in most patients. It has also engendered catch-up growth in many children, induced improvement in lung involvement secondary to Gaucher disease, and to some extent ameliorated episodes of bone pain. By virtue of treatment, many children who may have been severely affected no longer need to undergo splenectomy to treat hypersplenism, and therefore they are not at risk of bone involvement consequent to the loss of the preferred reservoir for lipid-laden ‘Gaucher cells’. However, enzyme treatment is ineffective in reversing neurological signs, requires a lifelong commitment to intravenous infusions, thereby reducing quality of life, and is relatively expensive for many national health schemes. Hence, alternative forms of treatment, such as substrate balance, are being explored. Symptomatic management, including orthopedic surgery, pain relief for bone pain and even splenectomy, still has importance for patients with Gaucher disease. In addition, there is the potential for bone marrow transplantation and, in the future, gene therapy to be curative, particularly for patients with the neuronopathic forms.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

Similar content being viewed by others

Notes

  1. The use of tradenames is for product identification only and does not imply endorsement.

References

  1. Beutler E, Grabowski GA. Glucosylceramide lipidoses. In: Scriver CR, Beudet AL, Sly WS, et al., editors. The metabolic basis of inherited diseases. 7th ed. New York: McGraw-Hill, 1995: 2641–70

    Google Scholar 

  2. Grabowski GA, Horowitz M. Gaucher’s disease: molecular, genetic and enzymological aspects. Clin Haematol 1997; 10: 635–56

    CAS  Google Scholar 

  3. Beutler E, Gelbart T. Gaucher disease mutations in non-Jewish patients. Br J Haematol 1993; 85: 401–5

    Article  PubMed  CAS  Google Scholar 

  4. Azuri J, Elstein D, Lahad A, et al. Asymptomatic Gaucher disease implications for large-scale screening. Genet Test 1998; 2: 297–9

    Article  PubMed  CAS  Google Scholar 

  5. Elstein D, Abrahamov A, Hadas-Halpern I, et al. Gaucher’s disease. Lancet 2001; 358: 324–7

    Article  PubMed  CAS  Google Scholar 

  6. Orvisky E, Sidransky E, McKinney CE, et al. Glucosylsphingosine accumulation in mice and patients with type 2 Gaucher disease begins early in gestation. Pediatr Res 2000; 48: 233–7

    Article  PubMed  CAS  Google Scholar 

  7. Dreborg S, Erikson A, Hagberg B. Gaucher disease: Norbottnian type. Eur J Ped 1980; 133: 107–18

    Article  CAS  Google Scholar 

  8. Ida H, Rennert OM, Iwasawa K, et al. Clinical and genetic studies of Japanese homozygotes for the Gaucher disease L444P mutation. Hum Genet 1999; 105: 120–6

    Article  PubMed  CAS  Google Scholar 

  9. Katz K, Mechlis-Frish S, Cohen IJ, et al. Bone scans in the diagnosis of bone crisis in patients who have Gaucher disease. J Bone Joint Surg Am 1991; 73: 513–7

    PubMed  CAS  Google Scholar 

  10. Elstein D, Itzchaki M, Mankin HJ. Skeletal involvement in Gaucher disease. Clin Haematol 1997; 10: 793–816

    CAS  Google Scholar 

  11. Pastores GM, Wallenstein S, Desnick RJ. Bone density in type 1 Gaucher disease. J Bone Miner Res 1996; 11: 1801–7

    Article  PubMed  CAS  Google Scholar 

  12. Carter LC, Fischmann SL, Mann J, et al. The nature and extent of jaw involvement in Gaucher disease: observations in a series of 28 patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998; 85: 233–9

    Article  PubMed  CAS  Google Scholar 

  13. Kerem E, Elstein D, Abrahamov A, et al. Pulmonary function abnormalities in type I Gaucher disease. Eur Respir J 1996; 9: 340–5

    Article  PubMed  CAS  Google Scholar 

  14. Brady RO, Barton NW, Grabowski GA. The role of neurogenetics in Gaucher disease. Arch Neurol 1993; 50: 1212–24

    Article  PubMed  CAS  Google Scholar 

  15. Goitein O, Elstein D, Abrahamov A, et al. Lung involvement and enzyme replacement therapy in Gaucher’s disease. Q J Med 2001; 94: 407–15

    Article  CAS  Google Scholar 

  16. NIH Technology Assessment Panel on Gaucher Disease. Gaucher disease: current issues in diagnosis and treatment. JAMA 1996; 275: 548–53

    Article  Google Scholar 

  17. Hollak CEM, van Weely S, van Oers MHJ, et al. Marked elevation of plasma chitotriosidase activity: a novel hallmark of Gaucher disease. J Clin Invest 1994; 98: 1288–92

    Article  Google Scholar 

  18. Young E, Chatterton C, Velodi A, et al. Plasma chitotriosidase activity in patients with Gaucher disease who have been treated either by bone marrow transplantation or by enzyme replacement therapy. J Inherit Metab Dis 1997; 20: 595–602

    Article  PubMed  CAS  Google Scholar 

  19. Krasnewich D, Dietrich K, Bauer L, et al. Splenectomy in Gaucher disease: new management dilemmas. Blood 1998; 91: 3085–7

    PubMed  CAS  Google Scholar 

  20. Zimran A, Elstein D, Schiffmann R, et al. Outcome of partial splenectomy in type I Gaucher disease. J Pediatr 1995; 126: 596–7

    Article  PubMed  CAS  Google Scholar 

  21. Lebel E, Itzchaki M, Hadas-Halpern I, et al. Outcome of total hip arthroplasty in patients with Gaucher disease. J Arthroplasty 2001; 16: 7–12

    Article  PubMed  CAS  Google Scholar 

  22. Ohashi T, Boggs S, Robbins P, et al. Efficient transfer and sustained high expression of the human glucocerebrosidase gene in mice and their functional macrophages following transplantation of bone marrow transduced by a retroviral vector. Proc Natl Acad Sci USA 1992; 89: 11332–6

    Article  PubMed  CAS  Google Scholar 

  23. Ringden O, Groth CG, Erikson A, et al. Ten years’ experience of bone marrow transplantation for Gaucher disease. Transplantation 1995; 59: 864–70

    PubMed  CAS  Google Scholar 

  24. Grabowski GA, Leslie N, Wenstrup R. Enzyme therapy for Gaucher disease: the first 5 years. Blood Rev 1998; 12: 115–33

    Article  PubMed  CAS  Google Scholar 

  25. Rosenthal DI, Doppelt SH, Mankin HJ, et al. Enzyme replacement therapy for Gaucher disease: skeletal responses to macrophage-targeted glucocerebrosidase. Pediatrics 1995; 96: 629–37

    PubMed  CAS  Google Scholar 

  26. Elstein D, Hadas-Halpern I, Itzchaki M, et al. Effect of low-dose enzyme replacement therapy on bones in Gaucher patients with severe skeletal involvement. Blood Cells Mol Dis 1996; 22: 104–11

    Article  PubMed  CAS  Google Scholar 

  27. Elstein D, Abrahamov A, Itzchaki M, et al. Low-dose high-frequency enzyme replacement therapy prevents fractures without complete suppression of painful bone crises in patients with severe juvenile onset type I Gaucher disease [commentary]. Blood Cells Mol Dis 1998; 24: 303–5

    Article  PubMed  CAS  Google Scholar 

  28. Ostlere L, Warner T, Meunier PJ, et al. Treatment of type 1 Gaucher’s disease affecting bone with aminohydroxypropylidene bisphosphonate (pamidronate). Q J Med 1991; 79: 503–15

    PubMed  CAS  Google Scholar 

  29. Wenstrup R, Bailey L, Grabowski GA, et al. Alendronate disodium improves bone mineral density in adults receiving enzyme replacement therapy (ERT) for Gaucher disease [abstract]. Am J Hum Genet 2001; 69: 674

    Google Scholar 

  30. Corssmit EP, Hollak CE, Endert E, et al. Increased basal glucose production in type I Gaucher disease. J Clin Endocrinol Metab 1995; 80: 2653–7

    Article  PubMed  CAS  Google Scholar 

  31. Elstein D, Hadas-Halpern I, Abrahamov A, et al. Reply to vom Dahl et al. Clinical monitoring after cessation of enzyme replacement therapy in M. Gaucher. Br J Haematol 2001; 113: 1086–7

    Article  Google Scholar 

  32. Elstein D, Klutstein MW, Lahad A, et al. Echocardiographic assessment of pulmonary hypertension in Gaucher disease. Lancet 1998; 351: 1544–6

    Article  PubMed  CAS  Google Scholar 

  33. Elstein D, Abrahamov A, Hadas-Halpern I, et al. Withdrawal of enzyme replacement therapy in Gaucher disease. Br J Haematol 2000; 110: 488–92

    Article  PubMed  CAS  Google Scholar 

  34. Beutler E, Demina A, Laubscher K, et al. The clinical course of treated and untreated Gaucher disease: a study of 45 patients. Blood Cells Mol Dis 1995; 21: 86–108

    Article  PubMed  CAS  Google Scholar 

  35. Mistry PK, Abrahamov A. A practical approach to diagnosis and management of Gaucher’s disease. Clin Haematol 1997; 10: 817–38

    CAS  Google Scholar 

  36. Elstein D, Abrahamov A, Zimran A. Ethical considerations for enzyme replacement therapy in neuronopathic Gaucher disease. Clin Genet 1998; 4: 179–84

    Google Scholar 

  37. Altarescu G, Hill S, Wiggs E, et al. The efficacy of enzyme replacement therapy in patients with chronic neuronopathic Gaucher’s disease. J Pediatr 2001; 138: 539–47

    Article  PubMed  CAS  Google Scholar 

  38. Vellodi A, Bembi B, de Villemeur TB, et al. Management of neuronopathic Gaucher disease: a European consensus. J Inherit Metab Dis 2001; 24: 319–27

    Article  PubMed  CAS  Google Scholar 

  39. Zimran A, Abrahamov A, Elstein D. Children with type I Gaucher disease: growing into adulthood with and without enzyme therapy. Isr Med Assoc J 2000; 2: 80–1

    PubMed  CAS  Google Scholar 

  40. Cox T, Lachmann R, Hollak C, et al. Novel oral treatment of Gaucher’s disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 2000; 355: 1481–5

    Article  PubMed  CAS  Google Scholar 

  41. Choudary PV, Tsuji S, Martin BM, et al. The molecular biology of Gaucher disease and the potential for gene therapy. Cold Spring Harb Symp Quant Biol 1986; 51 Pt 2: 1047–52

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Gaucher Clinic, Shaare Zedek Medical Center, PO Box 3235, Jerusalem, 91031, Israel

    Deborah Elstein, Aya Abrahamov, Altoon Dweck, Irith Hadas-Halpern & Ari Zimran

Authors
  1. Deborah Elstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Aya Abrahamov
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Altoon Dweck
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Irith Hadas-Halpern
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ari Zimran
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Deborah Elstein.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Elstein, D., Abrahamov, A., Dweck, A. et al. Gaucher Disease. Pediatr-Drugs 4, 417–426 (2002). https://doi.org/10.2165/00128072-200204070-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128072-200204070-00001

Keywords

Search

Navigation